Skip to content
CancerIndex

Publication

Fusion isoform multiplicity and impact on treatment outcomes in ALK-rearranged non-small cell lung cancer with next-generation tyrosine kinase inhibitors.

Damien Humbert, Adrien Buisson, Mathurine Basset, Anne-Claire Toffart, Luc Odier, Stéphane Hominal, Chloé Herreman, Sylvie Chabaud, Maurice Pérol, Anne Mc Leer, Aurélie Swalduz

Lung cancer (Amsterdam, Netherlands)Oct 1, 2026PMID 42691832doi:10.1016/j.lungcan.2026.109594 Journal ArticlepubmedProvenance
Source
PubMed
Retrieved
Sep 19, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260919-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

BACKGROUND: ALK-rearranged non-small cell lung cancer (NSCLC) reported controversies regarding the impact the ALK-fused genes on treatment outcome. Fusion isoforms are structural variants of the same fusion transcript. Recent evidence suggests that the presence of multiple isoforms within a single…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Candidate 1

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.